Philip C Schouten, Sandra Schmidt, Kerstin Becker, Holger Thiele, Peter Nürnberg, Lisa Richters, Corinna Ernst, Isabelle Treilleux, Jacques Medioni, Florian Heitz, Carmela Pisano, Yolanda Garcia, Edgar Petru, Sakari Hietanen, Nicoletta Colombo, Ignace Vergote, Shoji Nagao, Sabine C Linn, Eric Pujade-Lauraine, Isabelle Ray-Coquard, Philipp Harter, Eric Hahnen, Rita K Schmutzler
IMPORTANCE: Testing for homologous recombination deficiency is required for the optimal treatment of high-grade epithelial ovarian cancer. The search for accurate biomarkers is ongoing. OBJECTIVE: To investigate whether progression-free survival (PFS) and overall survival (OS) of patients with high-grade epithelial ovarian cancer treated with maintenance olaparib or placebo differed between patients with a tumor BRCA-like genomic profile and patients without a tumor BRCA-like profile...
April 1, 2024: JAMA Network Open